AssayIndex
Contributing laboratory

VendorInvestigate

The only contributor that routinely purchases material anonymously rather than accepting submitted samples. 601 reports in the index — 8.9 % of the total.

601 reportsgradient 32 minHigh-resolution MSrepeatability 0.30 pp
Section 1

Identification and method basis

Laboratory
VendorInvestigate
Short code in this index
VendorInvestigate
Location
Riga, Latvia
Founded
2022
Reports contributed
601
Share of index
8.9%
Purity gradient
32min
Mass resolution
High resolution (ESI-TOF / QTOF)
Stated turnaround
5–10 business days
Measured offset vs reference
-0.493 pp
Within-lab repeatability
0.30pp

VendorInvestigate's methodological contribution to the index is procedural rather than instrumental: it purchases material anonymously, through unattributed channels, and controls the chain of custody from checkout to injection. Ninety-four per cent of VendorInvestigate reports in the index are buyer-sourced, against an index average of 85 %, and none are supplier-supplied.

That matters because the index can measure the difference. Across all paired comparisons where the same lot was assayed from both a supplier-supplied sample and an independently purchased vial, the supplier-supplied result reads a mean 0.31 pp higher (n=88, 95 % CI 0.19 to 0.43). VendorInvestigate's record set is the cleanest available subset for anyone who wants to exclude that effect entirely, and several of the index's supplier scorecards use it as a sensitivity check.

VendorInvestigate also performs a gravimetric fill check — weighing the vial before and after reconstitution — which is the only direct measurement of label-claim compliance in the index. It reveals that under-fill is more common than over-fill by roughly three to one.

Measured bias is −0.11 pp on 91 paired comparisons. The 32-minute gradient is the longest in use here and slightly better resolving than the reference, which is the likely source of the small negative offset: a longer gradient separates more, and separating more lowers the apparent main-peak area.

Section 2

Methods offered

What a laboratory can measure decides what a record can establish. A submission that orders only purity produces a record that names nothing.

  • RP-HPLC purity (%area, 214 nm)
  • LC-MS identity (ESI-QTOF)
  • blind-purchase chain of custody
  • counter-ion by ion chromatography
  • label-claim verification by gravimetric fill check
Section 3

What this laboratory has measured

Reports 601
Median purity reported 98.49% n=599
Index median 98.99% n=6722
Batches touched 430
020406092.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=295.75–96.00 %: n=296.00–96.25 %: n=496.25–96.50 %: n=296.50–96.75 %: n=696.75–97.00 %: n=1097.00–97.25 %: n=2397.25–97.50 %: n=3597.50–97.75 %: n=4497.75–98.00 %: n=5998.00–98.25 %: n=4898.25–98.50 %: n=6798.50–98.75 %: n=7098.75–99.00 %: n=7199.00–99.25 %: n=5099.25–99.50 %: n=5099.50–99.75 %: n=2999.75–100.00 %: n=27median 98.49 Purity (% area) Reports
Figure 1. Distribution of purity figures reported by VendorInvestigate. This is not a distribution of material quality — it is a distribution of what this laboratory was sent, which is a different and unrepresentative sample. Compare its shape against another laboratory's rather than its position: a short gradient compresses the left tail because unresolved species are counted into the main peak.
Most-tested compounds hereReportsMedian purity
Semaglutide10298.37
BPC-1575198.79
Retatrutide4997.89
Tirzepatide4997.80
TB-5003499.00
Melanotan II2198.73
Ipamorelin1899.13
Semax1798.85
CJC-1295 (no DAC)1598.39
MK-677 (Ibutamoren mesylate)1598.26
GHRP-61299.22
KPV1198.70
Selank1198.65
PT-141 (Bremelanotide)1099.03
ARA-2901098.75
Liraglutide998.69
Section 4

Agreement with the other laboratories

Each row is a paired analysis: batches where this laboratory and another one both assayed the same physical lot. A difference on a matched pair is bias plus noise, and it is the only clean way to compare laboratories.

AgainstPaired lotsMean difference (pp)95 % limits of agreementWithin 0.5 pp
Janoshik380-0.493-1.27 to 0.2951%
PeptideMeter272-0.451-1.32 to 0.4254%
Medutest249-0.559-1.45 to 0.3344%
Nordanalyt174-0.498-1.26 to 0.2751%
Kestrel143-0.913-1.94 to 0.1121%

Positive means VendorInvestigate read higher. The full paired analysis, with its assumptions →

Section 5

Provenance of what this laboratory receives

A laboratory that mostly receives supplier-supplied samples produces a record set with a known upward pressure on it, however good its analysis is. This is a property of the submission channel and not of the laboratory.

ProvenanceReportsShareEvidentiary weight
Buyer-sourced56894.5%Strongest available evidence in this index.
Supplier-supplied00.0%Weaker evidence. Read with the caveat below.
Laboratory-retained335.5%Provenance documented, selection uncontrolled.
Section 6

Recent records from this laboratory

The 25 most recent of 601. All records from VendorInvestigate →
ReportCompoundSupplierLotQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042574TB-500ERPERP-2605-S80222026-Q399.542.9196.4Buyer-sourced1MARGINAL
AX-2026-042347SemaglutideHJHJ-2608-C39312026-Q398.803.41100.2Buyer-sourced1MARGINAL
AX-2026-041453RetatrutideQYBQYB-2604-B56602026-Q398.022.55Buyer-sourced1MARGINAL
AX-2026-041728CJC-1295 with DACQSCQSC-2602-E94742026-Q398.427.04Buyer-sourced1MARGINAL
AX-2026-041386BPC-157WWBWWB-2606-H39062026-Q399.324.8899.2Buyer-sourced1MARGINAL
AX-2026-041459RetatrutideQYBQYB-2604-B56602026-Q397.912.8492.2Buyer-sourced1MARGINAL
AX-2026-043100TirzepatideKPKP-2608-D59212026-Q398.275.3194.4Buyer-sourced2MARGINAL
AX-2026-042274SLU-PP-332HomopeptideHOMO-2602-Y28222026-Q398.714.72Laboratory-retained0PASS
AX-2026-042183IpamorelinHomopeptideHOMO-2608-A90452026-Q399.384.97Buyer-sourced1MARGINAL
AX-2026-043040RetatrutideKPKP-2607-H52192026-Q396.135.86Laboratory-retained2FAIL
AX-2026-041770SemaglutideFGPFGP-2602-M15082026-Q399.331.4890.3Buyer-sourced1MARGINAL
AX-2026-041849TB-500JEEPJEEP-2602-V34342026-Q399.733.6088.6Buyer-sourced2MARGINAL
AX-2026-042478Melanotan IISWBSWB-2603-A57072026-Q398.734.34Buyer-sourced1MARGINAL
AX-2026-043088IpamorelinKPKP-2606-D58872026-Q398.283.4491.0Buyer-sourced1FAIL
AX-2026-041653LiraglutideQSCQSC-2605-W86022026-Q398.825.95Buyer-sourced0PASS
AX-2026-042287GHRP-6HJHJ-2603-R22582026-Q398.792.4390.9Buyer-sourced2FAIL
AX-2026-042072SS-31 (Elamipretide)TFCTFC-2604-Y74722026-Q397.883.4789.5Buyer-sourced2FAIL
AX-2026-041935SemaglutideTFCTFC-2604-X43012026-Q398.544.5498.4Buyer-sourced1MARGINAL
AX-2026-041731CJC-1295 with DACQSCQSC-2602-E94742026-Q399.077.1899.6Buyer-sourced1MARGINAL
AX-2026-042544TesamorelinERPERP-2604-W72802026-Q398.803.88Buyer-sourced2FAIL
AX-2026-042280SLU-PP-332HomopeptideHOMO-2602-Y28222026-Q399.165.05105.8Buyer-sourced0PASS
AX-2026-041766SemaglutideFGPFGP-2602-M15082026-Q398.742.51Buyer-sourced2FAIL
AX-2026-043500BPC-157BCHBCH-2603-G64222026-Q397.864.82Buyer-sourced1FAIL
AX-2026-041327SemaglutideWWBWWB-2606-N31922026-Q398.704.78Buyer-sourced1MARGINAL
AX-2026-042346SemaglutideHJHJ-2608-C39312026-Q399.403.48Buyer-sourced1MARGINAL